MX2007013470A - Forma purificada de tanaproget. - Google Patents

Forma purificada de tanaproget.

Info

Publication number
MX2007013470A
MX2007013470A MX2007013470A MX2007013470A MX2007013470A MX 2007013470 A MX2007013470 A MX 2007013470A MX 2007013470 A MX2007013470 A MX 2007013470A MX 2007013470 A MX2007013470 A MX 2007013470A MX 2007013470 A MX2007013470 A MX 2007013470A
Authority
MX
Mexico
Prior art keywords
tanaproget
purified form
prepared
forms
purified
Prior art date
Application number
MX2007013470A
Other languages
English (en)
Inventor
Jean Louise Helom
Arkadiy Zinoviy Rubezhov
Bogdan Kazimierz Wilk
Ramarao Chatlapalli
Arwinder Nagi
John Potoski
Vladimir Dragan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37000404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007013470(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2007013470A publication Critical patent/MX2007013470A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proveen tanaproget micronizado, forma I purificada de tanaproget, y forma I purificada, micronizada de tanaproget; tambien se proveen composiciones que contienen una o mas de las formas de tanaproget preparado, metodos de uso de una o mas de las formas de tanaproget preparado, y equipos que contienen una o mas de las formas de tanaproget preparado.
MX2007013470A 2005-04-28 2006-04-26 Forma purificada de tanaproget. MX2007013470A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67573805P 2005-04-28 2005-04-28
PCT/US2006/015813 WO2006116498A2 (en) 2005-04-28 2006-04-26 Purified form of tanaproget

Publications (1)

Publication Number Publication Date
MX2007013470A true MX2007013470A (es) 2008-01-22

Family

ID=37000404

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007013470A MX2007013470A (es) 2005-04-28 2006-04-26 Forma purificada de tanaproget.

Country Status (14)

Country Link
US (1) US7786297B2 (es)
EP (1) EP1874743B1 (es)
JP (2) JP2008539254A (es)
CN (1) CN101184738B (es)
AR (1) AR053595A1 (es)
AU (1) AU2006241189B2 (es)
BR (1) BRPI0610156A2 (es)
CA (1) CA2603786A1 (es)
ES (1) ES2431324T3 (es)
GT (1) GT200600173A (es)
MX (1) MX2007013470A (es)
PE (1) PE20061322A1 (es)
TW (1) TW200716130A (es)
WO (1) WO2006116498A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101166533A (zh) * 2005-04-28 2008-04-23 惠氏公司 微粉化的tanaproget和含有它的组合物
DE602006007453D1 (de) 2005-04-28 2009-08-06 Wyeth Corp Zusammensetzungen mit mikronisiertem tanaproget
US7767668B2 (en) * 2005-04-28 2010-08-03 Wyeth Llc Micronized tanaproget, compositions, and methods of preparing the same
BRPI0610433A2 (pt) * 2005-04-28 2010-11-23 Wyeth Corp forma polimórfica ii de tanaproget, processos para preparar a mesma, e para preparar forma micronizada de um composto, composição farmacêutica, método de preparação de uma composição farmacêutica, e, uso da forma polimórfica ii de tanaproget ou da forma micronizada
CA2610767C (en) 2005-06-09 2014-09-23 Wyeth Tanaproget compositions containing ethinyl estradiol
JP2011507853A (ja) 2007-12-20 2011-03-10 テバ ウィメンズ ヘルス インコーポレイテッド 緊急避妊のための投与量レジメンならびに薬学的組成物およびパッケージ
WO2014143617A1 (en) * 2013-03-14 2014-09-18 Teva Women's Health, Inc. Deuterium-enriched tanaproget and processes for its preparation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011287A (es) * 1999-05-04 2003-07-14 American Home Prod Derivados de ciclotiocarbamato como moduladores de receptor de progesterona.
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
JP2005535628A (ja) 2002-06-25 2005-11-24 ワイス Ｐｒモジュレーターとしてのシクロチオカルバメート誘導体
JP2005535624A (ja) 2002-06-25 2005-11-24 ワイス ホルモン関連症状の治療におけるシクロチオカルバメート誘導体の使用
CN1953967B (zh) 2004-04-27 2013-03-13 惠氏公司 孕酮受体调节剂的纯化
AR049631A1 (es) * 2004-04-27 2006-08-23 Wyeth Corp Proceso de acoplamiento para la generacion de derivados reactivos de pirrol -2- carbonitrilo n- sustituidos con contenido de boro para producir biarilos
JP4980217B2 (ja) 2004-08-13 2012-07-18 ワイス・エルエルシー タナプロゲト誘導体、代謝産物、及びそれらの使用

Also Published As

Publication number Publication date
JP2008539254A (ja) 2008-11-13
TW200716130A (en) 2007-05-01
ES2431324T3 (es) 2013-11-26
WO2006116498A2 (en) 2006-11-02
AU2006241189B2 (en) 2012-01-19
AR053595A1 (es) 2007-05-09
PE20061322A1 (es) 2006-12-28
US20060247236A1 (en) 2006-11-02
CN101184738A (zh) 2008-05-21
AU2006241189A1 (en) 2006-11-02
CA2603786A1 (en) 2006-11-02
GT200600173A (es) 2006-11-22
BRPI0610156A2 (pt) 2016-08-16
JP2013231042A (ja) 2013-11-14
EP1874743A2 (en) 2008-01-09
WO2006116498A3 (en) 2006-12-14
US7786297B2 (en) 2010-08-31
CN101184738B (zh) 2012-05-23
EP1874743B1 (en) 2013-07-17

Similar Documents

Publication Publication Date Title
TW200732349A (en) Anti-OX40L antibodies and methods using same
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
MX2007008723A (es) Polipeptidos de yersinia spp y metodos de uso.
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
HK1097768A1 (en) Modified pyrimidine glucocorticoid receptor modulators
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
UA97502C2 (ru) Кристаллическая твердая основа разагилина
PL1682530T3 (pl) Podstawione pirolo-indole jako inhibitory PAI-1
TW200716622A (en) Substituted piperidines
TNSN07222A1 (en) Nematicidal compositions
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
HK1117746A1 (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
MX2010003200A (es) Composiciones de imatibnib estables.
TW200738649A (en) Calcilytic compounds
MX2010002028A (es) Metodos y composiciones para modular celulas t.
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
EA200800713A1 (ru) Аморфные твёрдые дисперсии
WO2008027600A3 (en) Imatinib compositions
TW200716130A (en) Purified form of tanaproget
WO2008150537A3 (en) Silica particles and methods of making and using the same

Legal Events

Date Code Title Description
FG Grant or registration